Short stature and pubertal delay in Duchenne muscular dystrophy

Archives of Disease in Childhood

Volumn 101, Issue 1, 2016, Pages 101-106

  Wood, Claire L ^a,b   Straub, Volker ^b   Guglieri, Michela ^b   Bushby, Kate ^b   Cheetham, Tim ^a,b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; HUMAN GROWTH HORMONE; SOMATOMEDIN C; TESTOSTERONE;

CHILD GROWTH; CORTICOSTEROID THERAPY; DELAYED PUBERTY; DUCHENNE MUSCULAR DYSTROPHY; GROWTH, DEVELOPMENT AND AGING; HUMAN; MUSCLE FUNCTION; PHYSICAL PERFORMANCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SHORT STATURE; TREATMENT FAILURE; ADOLESCENT; CHEMICALLY INDUCED; CHILD; COMPLICATION; GROWTH DISORDERS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PUBERTY, DELAYED;

ADOLESCENT; CHILD; GLUCOCORTICOIDS; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PUBERTY, DELAYED; TESTOSTERONE;

EID: 84952638700     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2015-308654     Document Type: Review

References (55)

1. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71:304-13.
2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
3. Moxley RT III, Pandya S, Ciafaloni E, et al. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010;25:1116-29.
4. Henricson EK, Abresch RT, Cnaan A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 2013;48:55-67.
5. Golumbek PT, Keeling RM, Connolly AM. Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Neuromuscul Disord 2007;17:376-84.
6. Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013;84:698-705.
7. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; (1): CD003725.
8. Dec. GW. Steroid therapy effectively delays Duchenne's cardiomyopathy. J Am Coll Cardiol 2013;61:955-6.
9. Markham LW, Kinnett K, Wong BL, et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008;18:365-70.
10. Balaban B, Matthews DJ, Clayton GH, et al. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005;84:843-50.
11. Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-55.
12. Lebel DE, Corston JA, McAdam LC, et al. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am 2013;95:1057-61.
13. Rutter MM, Collins J, Rose SR, et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord 2012;22:1046-56.
14. Bianchi ML, Biggar D, Bushby K, et al. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord 2011;21:298-303.
15. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23:1344-7.
16. Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA 1999;282:671-6.
17. Bothwell JE, Gordon KE, Dooley JM, et al. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr (Phila) 2003;42:353-6.
18. Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004;14:476-82.
19. Eiholzer U, Boltshauser E, Frey D, et al. Short stature: a common feature in Duchenne muscular dystrophy. Eur J Pediatr 1988;147:602-5.
20. Rapisarda R, Muntoni F, Gobbi P, et al. Duchenne muscular dystrophy presenting with failure to thrive. Arch Dis Child 1995;72:437-8.
21. Messina MF, Aguennouz M, Arrigo T, et al. Novel SHOX gene mutation in a short boy with Becker muscular dystrophy: double trouble in two adjacent genes. Horm Res 2008;69:124-8.
22. Nagel BH, Mortier W, Elmlinger M, et al. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatr 1999;88:62-5.
23. Sarrazin E, von der Hagen M, Schara U, et al. Growth and psychomotor development of patients with Duchenne muscular dystrophy. Eur J Paediatr Neurol 2014;18:38-44.
24. McDonald CM, Han JJ, Mah JK, et al. Corticosteroids and Duchenne muscular dystrophy: does earlier treatment really matter? Muscle Nerve 2012;45:777-9.
25. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-89.
26. Bushby K, Griggs R. FOR-DMD. Finding the Optimum Regimen for Duchenne Muscular Dystrophy. An NIH Funded Trial of Steroids. 2011. Clinical Trial. Gov ref NCT01603407.
27. Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011;77:444-52.
28. Tanner JM, Buckler JM. Revision and update of Tanner-Whitehouse clinical longitudinal charts for height and weight. Eur J Pediatr 1997;156:248-9.
29. Allen DB, Julius JR, Breen TJ, et al. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998;83:2824-9.
30. Barkan AL, DeMott-Friberg R, Samuels MH. Growth hormone (GH) secretion in primary adrenal insufficiency: effects of cortisol withdrawal and patterned replacement on GH pulsatility and circadian rhythmicity. Pituitary 2000;3:175-9.
31. Wong BL, Miller L, Hu SY, et al. Prediction equations based on arm measurements may overestimate standingheight in Duchenne Muscular Dystrophy (DMD) patients on glucocorticoid (GC) therapy. NM Disorders 2013;13:738-852.
32. Gauld LM, Kappers J, Carlin JB, et al. Height prediction from ulna length. Dev Med Child Neurol 2004;46:475-80.
33. Griffiths RD, Edwards RH. A new chart for weight control in Duchenne muscular dystrophy. Arch Dis Child 1988;63:1256-8.
34. Rogol AD. New facets of androgen replacement therapy during childhood and adolescence. Expert Opin Pharmacother 2005;6:1319-36.
35. Moorthy B, Papadopolou M, Shaw DG, et al. Depot testosterone in boys with anorchia or gonadotrophin deficiency: effect on growth rate and adult height. Arch Dis Child 1991;66:197-9.
36. Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med 2012;366:443-53.
37. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child 2002;87:93-6.
38. Lai HC, Fitz Simmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000;342:851-9.
39. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93:967-76.
40. Umlawska W, Prusek-Dudkiewicz A. Growth retardation and delayed puberty in children and adolescents with juvenile idiopathic arthritis. Arch Med Sci 2010;6:19-23.
41. Griggs RC, Moxley RT 3rd, Mendell JR, et al. Randomized, double-blind trial of mazindol in Duchenne dystrophy. Muscle Nerve 1990;13:1169-73.
42. Merlini L, Granata C, Ballestrazzi A, et al. Growth hormone evaluation in Duchenne muscular dystrophy. Ital J Neurol Sci 1988;9:471-5.
43. Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-10.
44. Fryburg DA. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol 1994;267:E331-6.
45. Song YH, Song JL, Delafontaine P, et al. The therapeutic potential of IGF-I in skeletal muscle repair. Trends Endocrinol Metab 2013;24:310-19.
46. Rutter MM, Collins J, Backeljauw PF, et al. P.11.15 Recombinant human insulin-like growth factor-I (IGF-I) therapy in Duchenne Muscular Dystrophy (DMD): A 6-month prospective randomized controlled trial. Neuromuscul Disord 2013;23:803.
47. Mason A, Wong SC, McGrogan P, et al. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm Res Paediatr 2011;75:8-13.
48. Landon C, Rosenfeld RG. Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment. Am J Dis Child 1984;138:388-91.
49. Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001;56:1075-9.
50. Welle S, Jozefowicz R, Forbes G, et al. Effect of testosterone on metabolic rate and body composition in normal men and men with muscular dystrophy. J Clin Endocrinol Metab 1992;74:332-5.
51. Poyrazoglu S, Gunoz H, Darendeliler F, et al. Constitutional delay of growth and puberty: from presentation to final height. J Pediatr Endocrinol Metab 2005;18:171-9.
52. Zucchini S, Wasniewska M, Cisternino M, et al. Adult height in children with short stature and idiopathic delayed puberty after different management. Eur J Pediatr 2008;167:677-81.
53. Didi M, Morris-Jones PH, Gattamaneni HR, et al. Pubertal growth in response to testosterone replacement therapy for radiation-induced Leydig cell failure. Med Pediatr Oncol 1994;22:250-4.
54. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81:4358-65.
55. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-9.